Silexion Reports SIL204 Preclinical Immune Sensitization Data, Phase 2/3 Trial Site Activated
SLXN sits 21% above its 52-week low of $1.5.
Summary
Silexion announced new preclinical data for SIL204 demonstrating multi-mechanism immune sensitization in KRAS-driven cancers and confirmed the first clinical site is active for its Phase 2/3 trial.
Key Events · Product Development and Regulatory · SLXN
-
New Preclinical Immune Sensitization Data
SIL204 treatment produced statistically significant upregulation of FAS (CD95) and downregulation of HLA-G in human KRAS-mutant pancreatic and NSCLC cell lines, across G12D, G12V, and G12C mutations.
-
Coordinated Multi-Mechanism Profile
Combined with prior MHC-I upregulation data, SIL204 now shows modulation of three key immune pathways — antigen presentation, death receptor restoration, and checkpoint reduction — supporting combination with anti-PD-(L)1 therapies.
-
Phase 2/3 Trial Site Activated
First clinical trial site initiated at Tel Aviv Sourasky Medical Center at the end of July 2026, advancing SIL204 into Phase 2/3 evaluation for locally advanced pancreatic cancer.
-
Strategic Context: Survival Signal
The positive pipeline update comes amid a going-concern warning, recent reverse split, and shareholder disputes — providing a much-needed scientific catalyst for the micro-cap company.
Analysis · SLXN · Life Sciences
Silexion disclosed new preclinical findings showing its lead siRNA candidate SIL204 upregulates the immune death receptor FAS and downregulates the immune checkpoint HLA-G across multiple KRAS-mutant cancer cell lines. Combined with previously reported MHC-I upregulation, the data suggest a coordinated immune-sensitizing effect that could enhance checkpoint inhibitor efficacy — a key differentiator in the competitive KRAS space. The company also confirmed activation of its first Phase 2/3 clinical site, marking a concrete step toward human data. For a micro-cap biotech with a going-concern warning and recent reverse split, positive pipeline news is a critical survival signal, though the preclinical nature and early trial stage temper immediate impact.
How filings like this one have moved
In the 30 days to Oct 10, 2026, 29.1% of the 1633 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $1.50 to $94.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.